Health-care companies fell after lackluster earnings for an obesity-drug maker and from one major drug-store chain.
Novo Nordisk shares plunged after its blockbuster Wegovy weight-loss drug missed sales expectations after the pharmaceutical giant offered bigger discounts to U.S. buyers.
CVS Health's Medicare business continued to struggle in the second quarter, fueling yet another cut to its full-year earnings outlook, a new $2 billion cost-cutting plan, and the departure of a top executive.
Medtronic disclosed that the Food and Drug Administration approved Simplera, the medical technology company's continuous glucose monitor.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
08-07-24 1754ET
